MyBiotech GmbH is a dynamic CDMO headquartered in Germany offering end-to-end development, manufacturing services, and cutting‑edge products for the biotechnology and pharmaceutical sectors. MyBiotech core competences lay in the formulation development, tech transfer, scale up and GMP compliant production of biotech and pharma products independently from their structure or route of administration with strong emphasis on easily scalable, GMP-compliant continuous proprietary manufacturing technologies. Today, with more than 40 professionals from different fields (e.g. pharmacy, chemistry, biotech and engineering), they maintain over 120 cooperation partners across the world in research and industry.
MyBiotech merge under one roof pharmaceutical and biotechnological R&D with formulation and pharma GMP manufacturing capabilities. Under Pharmaceutical and Particle Technology division, MyBiotech focuses on development of nano- and microparticles formulations with different drug delivery needs together with technology transfer and scale up services to increase formulations adherence to GMP standards. Additionally, the newly operated GMP-certified facility enables the development and manufacturing of products under GMP compliant standards. The GMP facility offers flexible infrastructure and scalable cleanroom ensuring seamless clinical batch production and ensuring quality, safety and regulatory readiness. Under Biotechnology division, MyBiotech focuses on fermentation of various microorganisms and their tailored and optimized (e.g. yield and efficiency) extraction processes by employing proprietary cell-rupture methods and equipment. MyBiotech continues to expand its footprint and strengthen its position in Europe and beyond with active participation in collaborative projects. MyBiotech vision is to remain a trusted, technology-driven partner for bio-pharma clients, bridging innovation with regulatory and market acceptance. MyBiotech multifaceted strength in Biotech, Pharma and Technology allows seamless bridging of upstream (bio)processing and downstream formulation offer clients comprehensive capabilities and rapid translation from lab to production.
MyB’s Role in the MACRAMÉ Project
MyBiotech undertakes the implementation of Use-Case 5 PLGA-based inhalable Antibiotics by providing PLGA and PLC nanoparticles loaded with ciprofloxacin to verify MACRAME’ approach suitability for quantification and characterisation of aerosol upon exposure of the in vitro lung models.
